A new blood test, reportedly using the Stockholm3 approach, shows higher detection of aggressive prostate cancer than current screening methods, according to a study cited by multiple outlets. The research compares performance against standard PSA-based testing. In a cohort of more than 12,000 men in Sweden, the blood test detects about 90% of aggressive prostate cancer cases. PSA testing is reported to detect about 74% of such cases in the same study. The findings suggest the blood test may improve identification of higher-risk disease relative to PSA screening alone, though the reports do not provide additional details such as follow-up duration, specific study design parameters, or how false positives and overdiagnosis compare across methods. The coverage frames the results as an improvement over existing screening performance, based on the stated detection rates from the study. Further information would be needed to assess broader clinical impact, including validation in other populations and assessment of outcomes beyond detection.